Blockade of CRTh2 can reduce allergic inflammation in rodent models of antigen-induced airway inflammation, allergic rhinitis, and atopic dermatitis, and may be effective in a subgroup of IgG4-RD patients with atopy. Here, PTGDR2 is linked to atopic eczema.